Figure 5.

Inhibition of Akt or ERK1/2 with Specific Inhibitors Attenuated the CSF-2-Induced Migratory Capacity of MSCs

(A–D) MSCs were pretreated with inhibitor V (A and C, 10 μM) or PD98059 (B and D, 20 μM) for 1 h prior to an additional 48-h treatment with 300 ng/mL CSF-2; subsequent changes in migratory capacity were measured via the transwell assay (A and B) and western blotting for MMP-2 and MMP-9 (C and D). (E) MSCs were treated with 300 ng/mL CSF-2 alone or were concomitantly transfected with shRNA targeting ERK1/2; subsequent changes in the migratory capacity were measured by the transwell assay. (F and G) MSCs were pretreated with inhibitor V (F, 10 μM) or PD98059 (G, 20 μM) for 1 h prior to an additional 48-h treatment with 300 ng/mL CSF-2; subsequent changes in the expressions of multiple EMT markers, such as snail and twist (F and G), were measured by real-time PCR. β-actin was used as the internal control. The data represent the mean ± SD from three independent experiments.